

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

UNITED STATES DISTRICT COURT
NORTHERN DISTRICT OF CALIFORNIA

NIKKI POOSHS,

Plaintiff,

v.

PHILIP MORRIS USA, INC., et al.,

Defendants.

No. C 04-1221 PJH

**ORDER GRANTING DEFENDANTS'
MOTION TO EXCLUDE EXPERT
TESTIMONY; ORDER GRANTING
DEFENDANTS' MOTION FOR
SUMMARY JUDGMENT IN PART AND
DENYING IT IN PART**

Defendants' motion to exclude expert testimony and motion for summary judgment came on for hearing on August 8, 2012. Plaintiff Nikki Pooshs appeared by her counsel John Wallace, Jason M. Rose, and Phyra McCandless; defendant Philip Morris USA, Inc. ("Philip Morris") appeared by its counsel Stanley D. Davis and Jennifer L. Brown; defendant R.J. Reynolds Tobacco Company ("RJR") appeared by its counsel Peter Larson; and defendant Hill and Knowlton Strategies, LLC ("H&K" – formerly Hill and Knowlton, Inc.) appeared by its counsel Stan G. Roman. Having read the parties' papers and carefully considered their arguments and the relevant legal authority, the court hereby GRANTS the motion to exclude expert testimony, and GRANTS the motion for summary judgment in part and DENIES it in part.

BACKGROUND

This is a product liability case, in which plaintiff Nikki Pooshs alleges that she developed lung cancer as a result of smoking cigarettes produced by cigarette manufacturers including defendants Philip Morris and RJR ("the manufacturer defendants"), the sale of which was publicly promoted and advertised by H&K. Plaintiff began smoking in 1953 when she was in junior high school, and finally quit smoking in

1 1991. She was diagnosed with chronic obstructive pulmonary disease in 1989, and again
2 in 1999; with periodontal disease in 1990; and with lung cancer in January 2003. She filed
3 the present lawsuit in January 2004.

4 In the complaint, plaintiff asserts ten causes of action – negligence, against the
5 manufacturers and H&K; products liability (defective design), against the manufacturers;
6 misrepresentation, against the manufacturers and H&K; fraud and deceit (intentional
7 misrepresentation), against the manufacturers and H&K; fraud and deceit (concealment),
8 against the manufacturers and H&K; fraud and deceit (false promise), against the
9 manufacturers and H&K; fraud and deceit (negligent misrepresentation), against the
10 manufacturers and H&K; concert of action (conspiracy), against the manufacturers and
11 H&K; and pre-1969 failure to warn, and off-label failure to warn, against the manufacturers.

12 Defendants now seek an order pursuant to Federal Rule of Evidence 702 excluding
13 testimony of plaintiff’s cigarette-design experts, and an order pursuant to Federal Rule of
14 Civil Procedure 56 granting summary judgment on plaintiff’s claims.

15 DISCUSSION

16 A. Motion to Exclude Expert Testimony

17 1. Legal Standard

18 A witness who has been qualified as an expert by knowledge, skill, experience,
19 training, or education may give an opinion on scientific, technical, or otherwise specialized
20 topics if (1) the expert’s scientific, technical, or other special knowledge will help the trier of
21 fact understand the evidence or determine a fact in issue, (2) the testimony is based upon
22 sufficient facts or data, (3) the testimony is the product of reliable principles and methods,
23 and (4) the witness has applied the principles and methods reliably to the facts of the case.”
24 Fed. R. Evid. 702; see also Daubert v. Merrell Dow Pharms., Inc., 509 U.S. 579 (1993).

25 The proponent of expert testimony bears the burden of establishing by a
26 preponderance of the evidence that the admissibility requirements are met. See Fed. R.
27 Evid. 702, Advisory Committee Notes. Although there is a presumption of admissibility,
28 Daubert, 509 U.S. at 588, the trial court is obliged to act as a “gatekeeper” with regard to

1 the admission of expert scientific testimony under Rule 702. Id. at 597; see also Kumho
2 Tire Co., Ltd. v. Carmichael, 526 U.S. 137, 147 (1999).

3 Thus, Daubert requires a two-part analysis. First, the court must determine whether
4 an expert's testimony reflects "scientific knowledge," whether the findings are "derived by
5 the scientific method," and whether the work product is "good science" – that is, whether
6 the testimony is reliable and trustworthy. Daubert, 509 U.S. at 590 & n.9, 593. Second,
7 the court must determine whether the testimony is "relevant to the task at hand." Id. at 597.

8
9 Scientific evidence is reliable if it is based on an assertion that is grounded in
10 methods of science – the focus is on principles and methodology, not on conclusions.
11 Metabolife Int'l, Inc. v. Wornick, 264 F.3d 832, 841 (9th Cir. 2001). In determining whether
12 an expert's reasoning or methodology is scientifically valid, the district court can consider
13 "many factors," including (1) whether a scientific theory or technique can be (and has been)
14 tested; (2) whether the theory or technique has been subjected to peer review and
15 publication; (3) the known or potential rate of error and the existence and maintenance of
16 standards controlling the techniques operation; and (4) whether the technique is generally
17 accepted. Daubert, 509 U.S. at 593-95; Fed. R. Evid. 702, 2000 Advisory Committee
18 Notes.

19 Nevertheless, depending on the type of expert testimony offered, these factors may
20 not be appropriate to assess reliability. Kumho Tire, 526 U.S. at 150. Other factors that
21 might be considered include whether an expert has unjustifiably extrapolated from an
22 accepted premise to an unfounded conclusion, see General Elec. Co. v. Joiner, 522 U.S.
23 136, 146 (1997); or whether an expert has adequately accounted for obvious alternative
24 explanations, see Claar v. Burlington Northern R. Co., 29 F.3d 499, 502 (9th Cir. 1994).

25 The trial court should be also mindful that reliability is not determined based on the
26 "correctness of the expert's conclusions but the soundness of his methodology." Stilwell v.
27 Smith & Nephew, Inc., 482 F.3d 1187, 1192 (9th Cir. 2007) (quotation omitted). The trial
28 court should ensure the expert "employs in the courtroom the same level of intellectual rigor

1 that characterizes the practice of an expert in the relevant field.” Kumho Tire, 526 U.S. at
2 152.

3 Rule 702’s second prong concern’s relevancy, or “fit.” See Daubert, 509 U.S. at
4 591. Expert opinion testimony is relevant if the knowledge underlying it has a “valid . . .
5 connection to the pertinent inquiry,” and it is reliable if the knowledge underlying it “has a
6 reliable basis in the knowledge and experience of [the relevant] discipline.” Id. at 592;
7 Kumho Tire, 526 U.S. at 149.

8 2. Defendants’ motion

9 Defendants now seek an order excluding the cigarette-design testimony of plaintiff’s
10 experts Dr. K. Michael Cummings and Dr. William A. Farone, on the ground that neither is
11 an expert in cigarette design. This testimony is relevant to plaintiff’s second cause of action
12 for products liability, which alleges “defective design.”

13 Both Dr. Cummings and Dr. Farone have testified in a number of cases brought by
14 smokers and ex-smokers against cigarette manufacturers, and both appear to be qualified
15 to testify as experts on certain subjects. However, the question here is whether their
16 testimony regarding cigarette design is reliable and trustworthy, and relevant to the case.

17 a. Motion to exclude testimony of Dr. Cummings

18 Dr. K. Michael Cummings is an epidemiologist with a focus on public health. Broadly
19 speaking, epidemiology is the study of the incidence, distribution, and control of disease in
20 a population. Dr. Cummings has an undergraduate degree in health education, and
21 graduate degrees (including a Ph.D.) in health education and health behavior.

22 Dr. Cummings is currently a Professor in the Department of Psychiatry and
23 Behavioral Sciences and a co-leader of the Tobacco Research Program in the Hollings
24 Cancer Center at the Medical University of South Carolina in Charleston, South Carolina,
25 where he has worked since October 2011. Prior to that, he worked for thirty years at the
26 Roswell Park Cancer Institute in Buffalo, New York, where he was a senior research
27 scientist and the Chairman of the Department of Human Behavior. During the same period,
28 he also held the position of Professor in the Department of Social and Preventive Medicine

1 at the State University of New York at Buffalo where he taught graduate-level courses.

2 In connection with the present case, Dr. Cummings submitted a report in which he
3 provides opinions “relating to tobacco epidemiology, tobacco use behaviors, consumer risk
4 perceptions, tobacco product marketing, addiction and tobacco documents, specifically the
5 industry conspiracy to belittle the known health risks and addictive nature of cigarette
6 smoking.” To this end, he provides opinions regarding the following: whether plaintiff was
7 addicted to cigarettes; the marketing of cigarette brands smoked by plaintiff; the cigarette
8 industry’s knowledge regarding issues of smoking and health, including the dangers of
9 smoking and addictiveness of cigarettes during the time that plaintiff smoked; and the
10 epidemiological evidence as it pertains to the cause of plaintiff’s illnesses.

11 Dr. Cummings states in his report that cigarettes containing nicotine can be
12 addictive; that a “key indicator of addiction” is persistent daily use; and that plaintiff meets
13 this criteria for addiction to nicotine based on evidence that she was a persistent daily
14 smoker for more than 35 years, and that when she switched to a lower-nicotine cigarette,
15 she compensated by smoking more cigarettes.

16 Dr. Cummings states further that cigarettes were designed to have relatively high
17 levels of nicotine so that smokers would smoke them, and that the design of cigarettes was
18 defective because they were engineered to facilitate the easy inhalation of smoke, and
19 because they contain nicotine and can be addictive. He states that the business records of
20 the cigarette manufacturers show that various brands of cigarettes were engineered in
21 ways that were intended to maintain a smoker’s addiction to nicotine which in turn would
22 lead to repeated exposure to the toxins in cigarette smoke. He located these internal
23 business records of the defendants by “using short-string Boolean-based methodologies.”
24 He also searched patents and “published literature.”

25 Dr. Cummings states that the manufacturers’ product design decisions were made
26 with the explicit purpose of making it difficult for smokers to control their smoking behavior,
27 once they were addicted to nicotine. He claims that it is “readily apparent” that “safer
28 commercially feasible designs have existed for decades, but have not been widely used

1 because of concerns over profits.” He quotes a statement of a Philip Morris executive to
2 the effect that “a cigarette that does not deliver nicotine cannot satisfy the habituated
3 smoker and cannot lead to habituation, and would therefore almost certainly fail,” and
4 opines that this shows that cigarette manufacturers preferred to keep smokers “habituated”
5 rather than changing their design to sell a cigarette that would not habituate the user.

6 Defendants do not object to Dr. Cummings’ testimony regarding the bulk of the
7 opinions in his report, but do argue that he should not be permitted to testify regarding
8 cigarette design, because he has no qualifications that would allow him to offer opinions on
9 that subject. Defendants also assert that his methodology in this regard is not sound, as it
10 consists solely of reviewing various documents that he himself selected, and producing a
11 summary of those documents. Defendants contend that such testimony would not assist
12 the jury, and that it is not sufficiently reliable to satisfy the requirements of Daubert.

13 In response, plaintiff asserts that Dr. Cummings is qualified to testify on subjects
14 related to his work, which plaintiff characterizes as “the cigarette manufacturers’ role in
15 getting young smokers addicted to nicotine in cigarettes, and how [d]efendants have
16 engineered cigarettes to influence smoking behavior.” She claims that Dr. Cummings has
17 devoted his professional career to studying the defendants’ internal documents, and has
18 thus been able to reach conclusions regarding the alleged decades-long effort to confuse
19 smokers and potential smokers about the contents of cigarettes, the health consequences
20 associated with long-term cigarette use, the effectiveness of advertising by defendants, and
21 the details of their efforts to convolute the truth about all of these factors.

22 Plaintiff contends that Dr. Cummings is qualified to testify about cigarette design
23 based on the fact that he is one of the nation’s foremost experts on nicotine addiction, and
24 cancer prevention as it relates to tobacco epidemiology, tobacco use behaviors, consumer
25 risk perceptions, tobacco product marketing, and “tobacco documents,” and the fact that he
26 has received numerous grants for his research, and has published many peer-reviewed
27 scientific papers that directly focus on cigarette design. Thus, plaintiff argues, Dr.
28 Cummings is well-qualified to testify regarding how variation in product design influences

1 smoking behavior. She argues further that because Dr. Cummings has provided trial
2 testimony in other cases on the areas on which he has been designated an expert in this
3 case – including cigarette design – he should also be admitted as an expert here.

4 Plaintiff also contends that Dr. Cummings' proffered testimony is reliable, as his
5 expertise in researching the internal and external statements of the tobacco industry to
6 determine what manufacturers knew about the risks of smoking has developed over the
7 past thirteen years. Over all, plaintiff asserts, Dr. Cummings has more than 30 years'
8 experience and expertise in "tobacco control and research of tobacco industry documents,"
9 and the fact that part of his opinion is based on his having summarized industry documents,
10 which is the type of material that experts in this field would normally rely on.

11 The court finds that the motion must be GRANTED as to Dr. Cummings' cigarette-
12 design opinions. It is plaintiff's burden to demonstrate the admissibility of her experts'
13 opinions. As an epidemiologist with expertise in health behavior and the use of cigarettes,
14 including the addictive properties of nicotine and the causes and effects of nicotine
15 addiction, Dr. Cummings is qualified to testify regarding those subjects. However, plaintiff
16 has failed to establish that Dr. Cummings is qualified to testify about cigarette design.

17 Neither the fact that Dr. Cummings has applied for and sometimes obtained grant
18 money to support tobacco-related research, or the fact that Dr. Cummings has authored
19 numerous papers, is sufficient to establish Dr. Cummings as an expert in cigarette design,
20 unless that research and those papers relate to the subject of cigarette design. The claim
21 that Dr. Cummings "contributed" to numerous "papers" related to the subject of cigarette
22 design is also meaningless unless plaintiff can establish what form his contributions took.
23 Indeed, Dr. Cummings has conceded that he has no training in cigarette design and that he
24 has never designed a cigarette or a cigarette filter.

25 Dr. Cummings does appear to be qualified, based on his review of the literature, to
26 testify regarding the cigarette industry's knowledge regarding the risks of smoking; and
27 regarding the fact that a cigarette that delivers less nicotine and/or other toxic substances
28 will be less risky to human health; and also regarding how a particular cigarette design

1 might influence smoking behavior. Nevertheless, since he is not qualified as an expert in
2 how to design cigarettes, his testimony would not assist the trier of fact in understanding or
3 determining whether the design of defendants' cigarettes was in fact defective. Moreover,
4 because Dr. Cummings is not qualified to testify regarding the cause of plaintiff's cancer, he
5 is also not qualified to provide opinions regarding whether plaintiff could have avoided
6 getting cancer if some alternative design had been available and she had switched to that
7 alternative design.

8 b. Motion to exclude testimony of Dr. Farone

9 Dr. William A. Farone is a chemist who worked for Philip Morris between 1976 and
10 1984. He has undergraduate and graduate degrees in chemistry, and a Ph.D. in physical
11 chemistry. He also has indicated, however, that he believes that the process of studying
12 for and obtaining a Ph.D. has qualified him to study almost any subject on his own and
13 become an expert on that subject. He considers his Ph.D. as "a license to do that in any
14 topic I choose as evidenced by the fact that many people have won Nobel prizes in multiple
15 fields, physics, chemistry, peace, economics." For this reason, he claims "expertise in a
16 wide variety of areas."

17 In his expert report, Dr. Farone describes himself as "a professional scientist with a
18 background in engineering." He also claims to have "training and experience" in the
19 "cigarette industry." He worked at Lever Brothers from 1967 to 1976, where he was
20 promoted to the position of Director of Scientific Research; and at Philip Morris USA from
21 1976 to 1984, where he became Director of Applied Research. In 1984 he left Philip Morris
22 to form Applied Power Concepts, Inc., which "develops and commercializes processes and
23 chemicals for environmental remediation of toxic contamination and alternative energy
24 technology." He is currently the Chairman of the Board and the Chief Technology Officer of
25 Applied Power Concepts, Inc. He states that he has published over 80 papers, including
26 some number of papers on "cigarette smoke toxicity and nicotine chemistry."

27 In connection with the present case, Dr. Farone submitted a report in which he
28 provides opinions on the "design decisions that go into the development of cigarettes,"

1 which decisions he categorizes as (1) “[i]ntentional choices about the types of tobacco, the
2 blends, and the portions of the tobacco plant included in the cigarette rod of each brand, as
3 well as the amount of reconstituted tobacco and expanded tobacco[;]” (2) “[i]ntentional
4 technical design choices for the rod and filter of each brand, including the length, diameter,
5 and amount of tobacco in the rod; the type of paper used . . . ; the composition of the filler
6 in the rod and the casings used to hold the rod material together [and] the filter and filter
7 paper, the ventilation of the filter, and the porosity of the filter[;]” (3) “[i]ntentional decisions
8 concerning the use of additives in each brand;” and (4) “[i]ntentional use of nicotine
9 technologies that affect the amount, form and impact of the nicotine in each brand of
10 cigarette[.]”

11 Dr. Farone opines that defendants designed cigarettes in ways that enhanced the
12 effect of nicotine on smokers – claiming that while he was at Philip Morris, it was clear to
13 him that modern cigarettes are designed as meticulously and thoroughly as drug products
14 are by pharmaceutical companies, and that defendants understood the “biochemical and
15 pharmacological properties of [their] products.” He asserts that ensuring delivery of a dose
16 of nicotine sufficient to create and sustain addiction was “a design criterion of the modern
17 cigarette,” which was achieved through means such as the “manipulation of nicotine levels
18 via technology[,] . . . decreasing particle size through combustion chemistry[,] . . .
19 increas[ing] inhalability through tobacco processing[,] . . . specification of flavorants,
20 additives, and smoke chemistry[,] . . . development of high-porosity paper . . . and other
21 characteristics to facilitate rapid and repeated product use.”

22 Dr. Farone also opines that Philip Morris and RJR had the capability of reducing the
23 level of carcinogens delivered in cigarette smoke, but elected to avoid design options to
24 accomplish this. He asserts that “[t]he intentional design of cigarettes to create and sustain
25 addiction has a direct, predictable consequence that a majority of current and foreseeable
26 users will suffer premature death and disability from the intended use of the cigarette
27 product[,]” because as smokers become dependent upon nicotine, their ability to stop
28 smoking is diminished significantly.

1 Defendants argue that Dr. Farone should not be permitted to testify as an expert
2 witness. First, they contend that he is not qualified to offer opinions regarding biochemistry
3 or pharmacology, or to otherwise testify regarding the effect of nicotine on the human body.
4 They note that he has not attended medical school, is not a pharmacologist, and does not
5 hold a degree in pharmacology; that he has never performed any research or published
6 any papers on pharmacology; and that he has never published a paper on nicotine and
7 ammonia. They also argue that he is not qualified to offer opinions regarding cancer
8 causation, as he is not a toxicologist, an epidemiologist, an oncologist, or a pathologist, and
9 is not board-certified in pulmonology, oncology, molecular biology, or physiology.

10 Defendants assert further that Dr. Farone’s proposed opinions on cigarette design
11 are unreliable, because his report does not clearly separate his cigarette-design opinions
12 from his opinions on a number of other topics, such as how defendants should have
13 marketed cigarettes, or his review of various company documents. Defendants contend
14 that it is difficult to ascertain what Dr. Farone’s cigarette-design opinions are, but that to the
15 extent they can be discerned, he appears to opine that cigarette design is flawed because
16 cigarette smoke is “inhalable,” because cigarettes deliver a “dose” of nicotine that can
17 cause smokers to become addicted, and because one or more dangerous components
18 could have been removed from cigarette products but were not.

19 Defendants point to two specific opinions expressed by Dr. Farone, and argue that
20 they are particularly unreliable. First, Dr. Farone opines that ammonia compounds in
21 cigarettes increase the rate of transmission to the brain (by a matter of “milliseconds”), and
22 that this makes cigarettes “defective” because he hypothesizes that it makes them more
23 addictive. However, defendants assert, because Dr. Farone is not qualified to opine on the
24 issue of addiction in general, or nicotine pharmacology in general, he has no basis for this
25 opinion, and has not provided any scientific basis to support this theory. Indeed,
26 defendants note, Dr. Farone acknowledges that two recent government-funded studies
27 (funded by the governments of Canada and the Netherlands) have concluded that there is
28 no support for the theory that the addition of ammonia facilitates the rate of absorption.

1 Second, Dr. Farone opines that defendants could have designed cigarettes to
2 reduce various constituents of smoke, in particular “tobacco-specific nitrosamines,” but also
3 aldehydes, polyaromatic hydrocarbons, and carbon monoxide. Defendants assert that
4 these opinions, too, are unreliable, because, Dr. Farone has repeatedly failed to test his
5 hypotheses regarding safer alternative designs, and, in fact, conceded in his deposition that
6 a reduction in tobacco-specific nitrosamines (which he described as “among the worst
7 compounds in tobacco smoke) had not made cigarettes any less harmful.

8 In addition, defendants note, neither Dr. Farone nor any of plaintiff’s other experts
9 has shown that even if designs with reduced nicotine or ammonia or other constituents
10 were made available, plaintiff and other smokers would use them instead of traditional
11 cigarettes. Indeed, defendants assert, plaintiff testified in her deposition that she tried the
12 cigarettes with less nicotine or that used filters that made it harder to draw the smoke, and
13 did not like them.

14 In opposition, plaintiff argues that Dr. Farone is well-qualified to testify as an expert
15 on the topics for which plaintiff will offer him. First, plaintiff contends that Dr. Farone is
16 qualified to testify regarding addiction and cancer causation as they relate to cigarette
17 design, because he is trained in chemistry and has published prolifically in the areas of
18 physics, chemistry, and biotechnology, and because he holds a number of chemical,
19 electrical, and biotechnology patents. Plaintiff also contends that based on his experience
20 at Philip Morris and his training and “other experience,” Dr. Farone is qualified to testify on
21 the pharmacology of nicotine, addiction, and cancer causation as they relate to cigarette
22 design. Plaintiff asserts that it is unnecessary that an expert be qualified “based simply on
23 an expert’s Ph.D. field,” and that Dr. Farone should be considered qualified based on his
24 “renown as an expert in cigarette design.”

25 Plaintiff argues further that even if the court accepts defendants’ argument that Dr.
26 Farone is not qualified to testify regarding pharmacology, he is nevertheless qualified to
27 testify about the chemistry of nicotine, and what, in his personal experience, Philip Morris
28 and R.J. Reynolds understood about the pharmacology of nicotine. Similarly, even though

1 Dr. Farone does not treat addiction, plaintiff claims he can be qualified to testify regarding
2 what “defendants” understood about nicotine and addiction and what “it” knew about lung
3 cancer “and its products,” and about what actions “defendants” took in response to “its”
4 understanding about nicotine in order to encourage addiction amongst “its” customers.

5 Plaintiff also contends that Dr. Farone’s proffered testimony is reliable, based on its
6 acceptance by Philip Morris, the National Cancer Institute, and the Food and Drug
7 Administration, as well as by numerous courts. As for Dr. Farone’s cigarette-design
8 opinions on ammonia and nicotine, plaintiff responds that his prior concession that he is not
9 an expert on nicotine addiction and responses to it is not a concession that he is not an
10 expert on the chemical composition of nicotine. As for the two government-funded studies
11 that found no connection between ammonia and nicotine absorption rate, plaintiff suggests
12 that those studies are of no account because they were funded by foreign governments.

13 Finally, plaintiff asserts that Dr. Farone’s opinions about designs that would have
14 reduced certain smoke constituents are reliable, and that defendants’ argument that Dr.
15 Farone has not tested his prototype is unavailing, as the testimony on which it is based
16 comes from a deposition held more than 13 years ago.

17 The court finds that the motion must be GRANTED. Plaintiff bears the burden of
18 proving the admissibility of her experts’ opinions, which she has not done here. In
19 particular, plaintiff has failed to establish that Dr. Farone is qualified to testify about
20 cigarette design, or about nicotine pharmacology, addiction or cancer causation.

21 Plaintiff appears to be offering Dr. Farone as both an expert witness and a percipient
22 witness (based on his employment at Philip Morris). However, Dr. Farone’s report – which
23 purports to be an expert report – mixes the two types of testimony. It is thus difficult to tell
24 whether Dr. Farone is basing his opinions on what he witnessed at Philip Morris, or on
25 some scientific reasoning (which in any event, he fails to explain). While Dr. Farone may of
26 course testify as a percipient witness regarding what he witnessed while he was employed
27 at Philip Morris, the court finds that he is not qualified to offer expert opinions about what
28 Philip Morris “understood” about cigarette design then or at any time. Moreover, since he

1 never worked for RJR or H&K, he has no personal knowledge of anything that transpired at
2 those companies.

3 As for Dr. Farone's opinions regarding cigarette design – including the opinion that
4 cigarettes are defective because the smoke is “inhalable,” because they deliver a “dose” of
5 nicotine that can addict smokers, and because they contain one or more dangerous
6 components that could have been removed but were not – plaintiff has provided no
7 evidence that Dr. Farone has tested his theories, or that his theories are consistent with
8 accepted scientific practices or protocols. Similarly, Dr. Farone’s theories about ammonia
9 and nicotine are not shown to be reliable, particularly in view of the recent research that
10 has refuted these theories. Dr. Farone has not provided any evidence that he has tested
11 his theories or that they are based on anything other than speculation.

12 As for Dr. Farone’s opinions regarding designs he claims would have reduced risk,
13 he has provided no evidence that any testing or studies have been conducted. It appears
14 to be his opinion that the “prototype” he suggests would have reduced the risk of smoking,
15 but this opinion is not supported by any accepted form of scientific proof.

16 As a chemist with knowledge of the chemistry of tobacco or smoked cigarettes, Dr.
17 Farone is qualified to testify regarding those subjects, to the extent he has addressed them
18 in his report, but not as to the elements or details of any particular cigarette design.
19 Because Dr. Farone appears to have no experience designing cigarettes, or in developing
20 any “feasible alternative design” that would be safer than any other design, he cannot be
21 considered qualified as an expert on cigarette design.

22 B. Motion for Summary Judgment

23 1. Legal Standard

24 A party may move for summary judgment on a “claim or defense” or “part of . . . a
25 claim or defense.” Fed. R. Civ. P. 56(a). Summary judgment is appropriate when there is
26 no genuine dispute as to any material fact and the moving party is entitled to judgment as a
27 matter of law. Id.

28 A party seeking summary judgment bears the initial burden of informing the court of

1 the basis for its motion, and of identifying those portions of the pleadings and discovery
2 responses that demonstrate the absence of a genuine issue of material fact. Celotex Corp.
3 v. Catrett, 477 U.S. 317, 323 (1986). Material facts are those that might affect the outcome
4 of the case. Anderson v. Liberty Lobby, Inc., 477 U.S. 242, 248 (1986). A dispute as to a
5 material fact is “genuine” if there is sufficient evidence for a reasonable jury to return a
6 verdict for the nonmoving party. Id.

7 Where the moving party will have the burden of proof at trial, it must affirmatively
8 demonstrate that no reasonable trier of fact could find other than for the moving party.
9 Soremekun v. Thrifty Payless, Inc., 509 F.3d 978, 984 (9th Cir. 2007). On an issue where
10 the nonmoving party will bear the burden of proof at trial, the moving party can prevail
11 merely by pointing out to the district court that there is an absence of evidence to support
12 the nonmoving party’s case. Celotex, 477 U.S. at 324-25. If the moving party meets its
13 initial burden, the opposing party must then set out specific facts showing a genuine issue
14 for trial in order to defeat the motion. Anderson, 477 U.S. at 250; see also Fed. R. Civ. P.
15 56(c), (e).

16 When deciding a summary judgment motion, a court must view the evidence in the
17 light most favorable to the nonmoving party and draw all justifiable inferences in its favor.
18 Anderson, 477 U.S. at 255; Hunt v. City of Los Angeles, 638 F.3d 703, 709 (9th Cir. 2011).

19 2. Defendants’ Motion

20 Defendants seek summary judgment as to the first through eighth, and tenth causes
21 of action. They argue that the design defect claims fail because plaintiff cannot prove her
22 injuries were caused by a defect in cigarette design, as distinguished from smoking
23 cigarettes in general; that the fraud claims fail because there is no evidence that plaintiff
24 relied on any particular representation made by defendants; that the concealment and
25 failure-to-warn claims fail because there is no evidence that any statement or warning
26 would have prevented plaintiff’s injuries; that the claims asserted against H&K fail because
27 it is immune from liability in tobacco product liability actions; and that the claim for “concert
28 of action” fails because civil conspiracy is not a separate tort under California law.

1 1. Design defect claims

2 “A manufacturer may be held strictly liable for placing a defective product on the
3 market if the plaintiff’s injury results from a reasonably foreseeable use of the product.”
4 Saller v. Crown Cork & Seal Co., Inc., 187 Cal. App. 4th 1220, 1231 (2010). Products
5 liability may be premised upon either of two categories of product defects – design defect
6 or manufacturing defect. Id.; see also McCabe v. American Honda Motor Co., 100 Cal.
7 App. 4th 1111, 1119 (2002). Here, plaintiff asserts a design defect claim.

8 A design defect exists when the product is built in accordance with its intended
9 specifications, but the design itself is inherently defective. See Barker v. Lull Eng’g Co., 20
10 Cal. 3d 413, 429 (1978). The plaintiff bears an initial burden of making “a prima facie
11 showing that the injury was proximately caused by the product’s design.” Id. at 431.

12 Defendants argue that summary judgment must be granted as to the defective
13 design claim or claims because plaintiff cannot prove her injuries were caused by a defect
14 in cigarette design, as distinguished from smoking cigarettes in general. Defendants assert
15 that the testimony of plaintiff’s cigarette design experts (Drs. Cummings and Farone) is
16 inadmissible, and that there is no evidence that a defect in the design caused her injuries.

17 The California Supreme Court has recognized two alternative tests for proving a
18 design defect under product liability law: the “consumer expectations test” and the
19 “risk-benefit test.” Soule v. General Motors Corp., 8 Cal. 4th 548, 566-67 (1994). In the
20 present case, plaintiff asserts a claim or claims of product liability based on the risk-benefit
21 test. Under the risk-benefit test, a product’s design is defective if the design embodies
22 “excessive preventable danger” – that is, the risk of danger inherent in the design
23 outweighs the benefits of such design. Barker, 20 Cal. 3d at 430; Ford v. Polaris Indus.,
24 Inc., 139 Cal. App. 4th 755, 766 (2006); see also Soule, 8 Cal. 4th at 562.

25 Nevertheless, regardless of whether the risk-benefit test or the consumer
26 expectations test is being employed, a plaintiff must prove that there was a design defect,
27 which actually caused the injury. O’Neil v. Crane Co., 53 Cal. 4th 335, 347 (2012); see
28 also Soule, 8 Cal. 4th at 572-73; Barker, 20 Cal. 3d at 431. The plaintiff must prove these

1 facts through expert testimony. See Whiteley v. Philip Morris, Inc., 117 Cal. App. 4th 635,
2 701-02 (2004).

3 A plaintiff may also bring a “negligent design” claim. However, where liability
4 depends on proof of a design defect, there is no practical difference between negligent
5 design and strict liability design. Lambert v. General Motors, 67 Cal. App. 4th 1179, 1185-
6 86 (1998). Under both strict liability and negligence, the plaintiff must prove that the defect
7 caused the injury. Merrill v. Navegar, Inc., 26 Cal. 4th 465, 479 (2001).

8 Here, the court finds that summary judgment must be GRANTED as to the second
9 cause of action for products liability, and also as to the first cause of action for negligence
10 to the extent that the allegation that defendants “negligently manipulated” cigarettes can be
11 construed as a claim of negligent design.

12 The evidence in this case shows that plaintiff smoked cigarettes manufactured by
13 the defendants, and that she developed lung cancer. However, there is no evidence that
14 the design of defendants’ cigarettes – as opposed to plaintiff’s smoking of cigarettes – was
15 a substantial factor in causing her lung cancer. See Whiteley, 117 Cal. App. 4th at 701-02.
16 While cigarettes may be considered generally harmful in the sense that smoking cigarettes
17 can contribute to the development of various diseases, including lung cancer, plaintiff has
18 not met her burden of showing, through admissible evidence, that it was the particular
19 design of defendants’ cigarettes that caused her lung cancer.

20 Moreover, the theory that cigarettes are defectively designed because they contain
21 nicotine is unpersuasive. There is general agreement that it is the nicotine that causes
22 smokers to become addicted, but nicotine is normally present in tobacco. Similarly, the
23 theory that cigarettes are defectively designed because the smoke from cigarettes is
24 intended to be “inhalable” is untenable, as “inhalable smoke” is an inherent feature of
25 cigarettes. Taken to its logical conclusion, the argument that cigarettes are defectively
26 designed because they deliver nicotine through the inhalation of smoke, if adopted, would
27 mean that the only remedy for this alleged design defect would be a ban on the
28 manufacture and sale of any cigarettes containing nicotine.

1 However, as the Supreme Court noted (in a different context), “Congress . . . has
2 foreclosed the removal of tobacco products from the market[.]” notwithstanding the general
3 acceptance of the adverse health consequences of using tobacco. See Food & Drug
4 Admin. v. Brown & Williamson Tobacco Corp., 529 U.S. 120, 137-38 (2000).

5 2. Fraud, concealment, and failure to warn claims

6 Defendants assert that summary judgment must be granted as to the fraud,
7 concealment, and failure-to-warn claims, because plaintiff has insufficient evidence to
8 support the elements of those claims. Plaintiff asserts four claims of affirmative
9 misrepresentation, in the third, fourth, sixth, and seventh causes of action; a claim of
10 concealment, in the fifth cause of action; and two claims of failure to warn – pre-1969
11 failure to warn and off-label failure to warn, in the ninth and tenth causes of action.¹

12 a. Claims of affirmative misrepresentation

13 To establish any of her claims of misrepresentation, plaintiff must prove actual
14 reliance and causation of injury. See Lazar v. Superior Court, 12 Cal 4th 631, 638 (1996);
15 Mirkin v. Wasserman, 5 Cal. 4th 1082, 1091-92 (1993). “‘Reliance’ . . . in the ordinary fraud
16 context” means “reliance on a statement for its truth and accuracy.” Kwikset Corp. v.
17 Superior Court, 51 Cal. 4th 310, 327 n.10 (2011).

18 The court finds that summary judgment must be GRANTED as to the third, fourth,
19 sixth, and seventh causes of action for affirmative misrepresentation, because plaintiff has
20 provided no evidence that she relied on any particular representation made by the
21 defendants.

22 In the complaint, plaintiff cites to only one specific representation regarding the
23 safety of smoking cigarettes. This is a document that was released/published by various
24 tobacco companies in January 1954 – the “Frank Statement to Cigarette Smokers” – which
25 allegedly appeared in approximately 450 newspapers located in major metropolitan areas
26 across the United States.

27 _____
28 ¹ Defendants do not challenge claim of pre-July 1969 failure-to-warn.

1 The “Frank Statement,” which is reproduced in the complaint, states, among other
2 things, that medical research indicates many possible causes of lung cancer; that
3 authorities do not agree as to what that cause is; that there is no proof that cigarette
4 smoking is one of the causes; that smoking tobacco is relaxing; that tobacco companies
5 are interested in cooperating with “those whose task it is to safeguard the public health;”
6 and that the tobacco companies are joining forces to establish the “Tobacco Industry
7 Research Committee,” for the purpose of researching “all phases of tobacco use and
8 health.”

9 Plaintiff testified, however, that she did not rely on the “Frank Statement.” Nor has
10 plaintiff provided evidence that she relied on any other affirmative statements by
11 defendants, or that any specific information that was not disclosed would have affected her
12 decisions if she had been aware of it. In her deposition, plaintiff testified that over the years
13 she had seen/heard representations regarding smoking, and had relied on those
14 representations in deciding to begin smoking and to continue doing so. Such
15 representations include newspaper articles that assertedly convinced her it was an open
16 question whether there were negative health effects from smoking cigarettes; commercials
17 and advertisements she saw as a child, which she claims persuaded her that smoking
18 would turn her into a mature and independent adult; and statements in advertisements,
19 which she contends convinced her that smoking cigarettes was safe and healthy.

20 Nevertheless, plaintiff was unable to identify any specific misleading statements
21 relating to smoking or health. At most, her testimony was that various advertisements
22 presented smoking in a way that made it appear attractive or glamorous. However, such
23 representations are not affirmative statements about the health effects of smoking.

24 There is no evidence that plaintiff relied on any affirmative statement of any
25 defendant, including the statements in the Joint Statement. Plaintiff alleges in the
26 complaint that “the public” was misled by the Joint Statement, but not that she herself was
27 misled by it. Nor did she testify that she ever saw it, read it, heard about it, or relied on it.
28 Indeed, she testified that she does not recall having ever read or heard (much less relied

1 on) any specific statement regarding smoking and health.

2 Because it is the plaintiff's burden in this case to plead and prove fraud with
3 particularity, she must establish facts that show how, when, where, to whom, and by what
4 means the alleged misrepresentations were tendered. Fed. R. Civ. P. 9(b); see also
5 Conrad v. Bank of America, 45 Cal. App. 4th 133, 156 (1996). In addition, a plaintiff cannot
6 oppose a motion for summary judgment (on a fraud claim) on allegations of fraud that were
7 never pled with particularity in the first place. See Wasco Prods., Inc. v. Southwall Techs.,
8 Inc., 435 F.3d 989, 990-92 (9th Cir. 2006) (citing cases); Kaplan v. Rose, 49 F.3d 1363,
9 1369-70 (9th Cir. 1994).

10 b. Claim of concealment

11 As with fraud claims generally, to establish a claim of concealment, plaintiff must
12 prove actual reliance and causation of injury. See Lazar, 12 Cal 4th at 638; Mirkin, 5 Cal.
13 4th at 1091-92. For claims alleging fraudulent concealment or omission, a plaintiff shows
14 reliance by proving that had the allegedly omitted information been disclosed, he/she would
15 have acted differently. See Rivera v. Philip Morris, Inc., 395 F.3d 1142, 1154-55 (9th Cir.
16 2005); Mirkin, 5 Cal. 4th at 1093.

17 Defendants argue that summary judgment must be granted on the claim of
18 concealment because there is no evidence that plaintiff relied on any particular
19 representation or that she would have acted differently had she been given different or
20 additional information. In general, defendants assert, plaintiff testified that she chose what
21 brand to smoke based on what brands other people were smoking (her father, her friend's
22 mother), and later, on brands recommended by SmokEnders (a smoking cessation
23 program). She also testified that she chose cigarette brands because of taste, and smoked
24 filter cigarettes because the filter kept the tobacco bits from getting in her mouth, not
25 because she believed the cigarettes with filters were safer.

26 Defendants argue that given the lack of evidence that plaintiff's decision to smoke –
27 or not to smoke – particular brands of cigarettes was made based on statements made by
28 the tobacco companies, she cannot show that she would have chosen other brands (or

1 would have chosen not to smoke) if she had been given other information.

2 Defendants also note that plaintiff has conceded that she received information about
3 the health risks of smoking – such as the information in the 1964 Surgeon General’s report
4 that smoking was a cause of fatal illnesses; the recommendation from her doctor in 1964
5 that she not smoke during her first pregnancy; the Labeling Act warnings in the late 1960s;
6 the requests by her children in the early 1970s that she stop smoking; and the information
7 she likely heard in the late 1970s or early 1980s, while she was working in a doctor’s office,
8 regarding the health risks of smoking. Defendants assert, however, that notwithstanding all
9 this input over the years, plaintiff never acted on the warnings about health risks.

10 Based on this, defendants argue that she cannot prove that she would have acted
11 any differently had the cigarette companies provided any additional information about the
12 health effects of smoking at any time during that period. Plaintiff finally quit smoking in
13 1991, but defendants note that plaintiff’s ex-husband, son, and daughter all testified that
14 nothing anyone could have said would have convinced her to quit smoking.

15 In opposition, plaintiff asserts that there is ample evidence that she would have
16 smoked a safer cigarette if defendants had manufactured one. She points to her
17 participation in the SmokEnders program, and her testimony that while she was in the
18 program she switched to lower-nicotine, lower-tar cigarettes because she believed such
19 cigarettes were healthier. She also notes that she testified that she routinely checked
20 cigarette packages for nicotine and tar content in an effort to smoke healthier cigarettes.

21 The court finds that the motion must be DENIED as to the fifth cause of action for
22 concealment and the tenth cause of action for failure to warn because triable issues
23 preclude summary judgment. In particular, disputed issues remain as to whether plaintiff
24 might have made different decisions at various times had she been aware of certain health
25 risks, or whether she would have smoked a “safer” cigarette had defendants manufactured
26 one.

27 c. Claim of off-label failure to warn

28 California recognizes failure to warn as a species of design defect products liability.

1 Saller, 187 Cal. App. 4th at 1238. “Under the failure-to-warn theory, a product may be
2 defective even though it is manufactured or designed flawlessly.” Id. Strict liability failure
3 to warn requires the plaintiff to prove that the defendant did not adequately warn of a
4 particular risk that was known or knowable in light of the generally recognized and
5 prevailing best scientific and medical knowledge available at the time of the manufacture
6 and distribution.” Id. at 1239; see also Anderson v. Owens-Corning Fiberglass Corp., 53
7 Cal. 3d 987, 1002 (1991). The plaintiff must prove that the defendant's failure to warn was
8 a substantial factor in causing his or her injury. Huitt v. So. California Gas Co., 188 Cal.
9 App. 4th 1586, 1604 (2010).

10 Defendants argue that summary judgment must be granted on the claim of failure to
11 warn because there is no evidence that plaintiff relied on any particular representation or
12 that any statement or warning would have prevented her injuries. A defendant is not liable
13 for an alleged failure to warn if the evidence shows that “the injury would have occurred
14 even if the defendant had issued adequate warnings.” Id.

15 As with the claim of concealment, defendants contend that plaintiff has no evidence
16 that she would have acted differently had she been given different or additional information.
17 They assert that the evidence shows that plaintiff chose what brand to smoke based on the
18 brands other people were smoking and also based on SmokEnders’ recommendations.
19 She also chose cigarette brands because of taste and convenience, not because she
20 believed the cigarettes with filters were safer. Thus, defendants assert, plaintiff cannot
21 show that she would have chosen other brands (or would have chosen not to smoke) if she
22 had been given other information.

23 Defendants again note that plaintiff received general information about the health
24 risks of smoking from a number of different sources, starting as early as 1964, and that
25 notwithstanding this input over the years, never acted on the warnings about health risks.
26 Based on this, defendants contend that plaintiff cannot show that she would have acted any
27 differently had the cigarette companies provided warnings at any time during that period.

28 As with the claim of concealment, the court finds that the motion must be DENIED

1 as to the failure-to-warn claim because disputed issues of fact remain as to, e.g., whether
2 plaintiff might have made different decisions at various times had she been aware of certain
3 health risks, whether she would have smoked a “safer” cigarette had defendants
4 manufactured one, or whether the alleged failure to warn was a substantial factor in
5 plaintiff’s injuries.

6 The court finds further that plaintiff’s failure-to-warn and concealment claims which
7 are based on facts after July 1, 1969, are not preempted by the Labeling Act. The Labeling
8 Act required the placement of warning labels on cigarette packages beginning in 1966.
9 Congress itself drafted the warning language, which it considered “necessary and
10 sufficient” to warn the public. See 15 U.S.C. § 1333; see also Altria Group, Inc. v. Good,
11 555 U.S. 70, 76-78 (2008).

12 In order that the warnings would be uniform, Congress precluded any warnings on
13 cigarette packages other than the ones it had drafted, and also provided that “[n]o
14 requirement or prohibition based on smoking and health shall be imposed under State law
15 with respect to the advertising or promotion of any cigarettes the packages of which are
16 labeled in conformity with the provisions of this chapter.” 15 U.S.C. § 1334(a), (b). This
17 express preemption, which became effective July 1, 1969, preempts state common law
18 actions that would impose such labeling “requirements or prohibitions” after that date.
19 Cipollone v. Liggett Group, Inc., 505 U.S. 504, 521-23 (1992).

20 Here, defendants note that the ninth cause of action is limited to “pre-1969 failure to
21 warn,” but assert that the first cause of action for negligence appears to allege a breach of
22 the duty to warn that is not limited by time. See Cplt ¶ 29. Defendants contend that to the
23 extent that plaintiff is attempting to assert a post-1969 claim of failure to warn, that claim is
24 preempted by the Labeling Act.

25 In opposition, plaintiff concedes that claims of post-1969 failure-to-warn through
26 advertising and promotion are preempted. However, she asserts that neither the ninth
27 cause of action for pre-1969 failure to warn, nor any other cause of action based on facts
28 prior to July 1, 1969, is preempted, because the Labeling Act does not preempt pre-1969

1 claims. Specifically, she contends that the first cause of action for negligence and the tenth
2 cause of action for off-label failure-to-warn are not preempted, as Cipollone narrowly
3 preempts only post-1969 failure to warn claims through advertising and promotion – and
4 her negligence claim is not a post-1969 failure to warn claim.

5 Under Cipollone, claims of failure-to-warn through advertising and promotion are
6 preempted, as are claims that defendants made statements or used images in cigarette
7 advertising or promotional materials that tended to minimize the health hazards associated
8 with smoking or that tended to glamorize smoking or make it seem attractive or positive.
9 Cipollone, 505 U.S. at 524, 527. However, a claim of fraudulent concealment or failure-to-
10 warn is not preempted if it relies on a state-law duty to disclose facts through channels of
11 communication other than advertisement or promotion. Id. at 528. Thus, to the extent that
12 plaintiff is asserting pre-1969 failure to warn, or post-1969 failure to warn that is based on a
13 duty to disclose facts other than through advertising and promotion, such claims are not
14 preempted and may proceed.

15 3. Claims asserted against H&K

16 Defendants contend that the claims asserted against H&K (first, and third through
17 eighth causes of action) fail because H&K is immune from liability in tobacco product
18 liability actions.

19 In 1987, the California Legislature enacted former section 1714.45 of California's
20 Civil Code (“the Immunity Statute”), providing that “[i]n a product liability action” a court
21 could not require a manufacturer or seller to pay damages for injuries caused by certain
22 products, including sugar, butter, and tobacco products, that are inherently unsafe and
23 known to be unsafe by the ordinary consumer of that product, except for claims alleging
24 manufacturing defects or breach of express warranty. Stats.1987, ch. 1498, § 3, p. 5778.

25 Ten years later, the Legislature repealed the Immunity Statute as it applied to
26 manufacturers of tobacco products “and their successors in interest” and to “tobacco
27 industry research organizations” – but not as to “sellers.” Stats.1997, ch. 570, § 1; see
28 Naegele v. R.J. Reynolds Tobacco Co., 28 Cal. 4th 856, 861-62 (2002). However, the

1 entities targeted by the amendment remain protected for actions during the ten-year period
2 between 1988 and 1998. Naegele, 28 Cal. 4th at 860. The Immunity Statute bars all
3 claims “however labeled,” and in particular applies to fraud claims as well as more
4 traditional “product liability” claims. Id. at 863, 867.

5 Defendants contend that because H&K is neither a tobacco manufacturer nor a
6 “tobacco industry research organization,” it is protected by the immunity set forth in the
7 statute, and is entitled to summary judgment on all claims. They assert that the statute, as
8 amended, reflects the Legislature’s intent to make clear that tobacco product liability
9 actions could proceed against tobacco manufacturers, their successors, and tobacco
10 industry research organizations, but no one else. Defendants contend that because H&K is
11 not a tobacco manufacturer or successor, and is not a tobacco industry research
12 organization, it is entitled to immunity.

13 In opposition, plaintiff asserts that H&K is not shielded from liability by Civil Code
14 § 1714.45. Plaintiff’s position is that because this immunity was originally extended only to
15 “manufacturers” and “sellers” of the listed products and not to any other entities, there was
16 never a bar to suing any entity other than a manufacturer or seller of one of the listed
17 products (which included tobacco), and that because H&K is not a manufacturer or a seller
18 of any consumer product, it never was shielded from liability.

19 H&K is a company that is alleged to have “operated as a public relations agent for
20 and on behalf of” the cigarette manufacturer defendants, “fostering smoking . . . as an
21 acceptable social norm and rite of passage into adulthood.” Cplt ¶ 12. In other words,
22 H&K is alleged to have acted as the agent for the cigarette companies, and to have
23 publicized false information regarding smoking. H&K is not alleged to have manufactured
24 or sold cigarettes, but (at most) to have aided and abetted the manufacturers. However,
25 plaintiff nowhere asserts that H&K was acting independently in connection with any of the
26 claims alleged.

27 Section 1714.45 provides immunity from claims that tobacco products are defective
28 (and has been interpreted to include claims of fraud and misrepresentation based on the

1 conduct of the defendants). Thus, to the extent that H&K was acting as an agent for the
2 manufacturer defendants in connection with the claims alleged in the complaint, it is not
3 immune, and the motion must be DENIED.

4 4. Claim for “concert of action”

5 Defendants argue that the eighth cause of action for “concert of action” fails because
6 it is in essence a claim for civil conspiracy which cannot be pled as a separate tort under
7 California law. See Applied Equip Corp. v. Litton Saudi Arabia Ltd., 7 Cal. 4th 503, 510
8 (1994). Alternatively, defendants argue, under Sindell v. Abbott Labs., 26 Cal. 3d 588
9 (1980), “concert of action” is simply another theory of joint or group liability based on
10 participation in some joint activity, and cannot be applied to facts involving injury by a
11 product. See id. at 603-06 (injury caused by diethylstilbestrol (“DES”)); see also Cadlo v.
12 Owens-Illinois, Inc., 125 Cal. App. 4th 513, 521-22 (2004) (asbestos); Setliff v. E.I. du Pont
13 de Nemours & Co., 32 Cal. App. 4th 1525, 1534-38 (chemical exposures).

14 In opposition, plaintiff argues that under California law, she is entitled to bring a
15 claim for alternative liability. See Sindell, 26 Cal. 3d at 594-95, 610-11 (alternative liability
16 doctrine of “conspiracy”); Brown v. Superior Court, 44 Cal. 3d 1049-1060-70 (1988)
17 (alternative theories of liability as causes of action). Plaintiff claims that defendants have
18 misstated California law regarding the applicable recovery theories of liability, such as
19 concert of action and conspiracy, and asserts that the court in Sindell expanded plaintiffs’
20 abilities to recover in product liability actions. Plaintiff argues that because smoking-caused
21 lung cancer is an “aggregate dose” disease like asbestos-related cancer, she should be
22 able to allege a “concert of action” claim, as her injuries are the direct and proximate result
23 of defendants’ “concerted actions.”

24 The court finds that defendants’ motion must be GRANTED. Civil conspiracy is not
25 recognized as an independent cause of action in California. See Applied Equip. Corp., 7
26 Cal. 4th at 510. Plaintiff’s argument appears to be that because she smoked so many
27 different brands of cigarettes, and is unable to identify the manufacturer of the brand or
28 brands that caused her cancer, the defendants can be held liable collectively without proof

1 of causation. Courts refer to this doctrine, variously, as “alternative liability,” “industry-wide
2 (or ‘enterprise’ liability;” “market share liability,” “concert of action,” and “conspiracy.” See
3 Chavers v. Gatke Corp., 107 Cal. App. 4th 606, 609 (2001); see also Sheffield v. Eli Lilly &
4 Co., 144 Cal. App. 3d 583. 593 (1983).

5 “Market share liability” is a doctrine under which “the traditional prerequisite of
6 identifying the manufacturer of the injury-causing product is eliminated when the product is
7 a generic item produced by several manufacturers.” Mullen v. Armstrong World Indus.,
8 Inc., 200 Cal. App. 3d 250, 255 n.6 (1988) (quotation and citation omitted). In such cases,
9 the plaintiffs need allege only the “inability to identify the actual manufacturer and join as
10 defendants those manufacturers that compose a ‘substantial share’ of the market.” Id. The
11 plaintiffs then proceed with their case against those members of the industry that are
12 named as defendants. This theory shifts the burden of proof to each manufacturer to prove
13 its innocence. Id.

14 If, after proceeding against the industry in this manner, the plaintiff successfully
15 establishes liability, damages are apportioned among defendants on the basis of each
16 defendant's share of the product market. The resultant “market share liability” imposed
17 thus “approximate[s each manufacturer's] responsibility for the injuries caused by its own
18 products.” A defendant can avoid liability only by proving that it did not produce the specific
19 product that harmed the plaintiff. Id.

20 One of the predicates for Sindell liability is that there be no common discernible
21 distinguishing features or characteristics of the instrumentalities produced by the industry
22 defendants. For example, in Sindell, the court emphasized that it was dealing with
23 “fungible goods” – specifically, a drug produced “from an identical formula.” Sindell, 26 Cal.
24 3d at 610-11.

25 To date, the “market share” theory of product liability has been held to reach
26 only “fungible goods,” and in only two narrow categories – “truly generic” goods, which are
27 produced from an identical formula, such as DES, and “generally fungible” goods such as
28 asbestos products composed of a specific asbestos fiber in a specific percentage. See

1 Wheeler v. Raybestos-Manhattan, 8 Cal. App. 4th 1152, 1156 (1992). However, products
2 such as those made with friable asbestos used for various purposes in home construction,
3 and which have varying toxicities; latex gloves; and solvents are not fungible products.
4 See, e.g., Mullen, 200 Cal. App. 3d at 257 (friable asbestos products); Kennedy v. Baxter
5 Healthcare Corp., 43 Cal. App. 4th 799, 811-12 (1996) (latex gloves); Setliff, 32 Cal. App.
6 4th at 1536 (“volatile organic compounds” in “paint solvents, strippers, and glue products”).

7 Here, plaintiff is attempting to extend “market share liability” from the DES field of
8 Sindell to the tobacco/cigarette industry proceeds on the premise that DES and cigarettes
9 are simple equivalents. This is far from being the case. DES is produced according to a
10 specific formula, and (according to the description in Sindell) the result does not differ
11 appreciably from manufacturer to manufacturer. By contrast, in the present case, plaintiff is
12 asserting that defendants “manipulated” the levels of nicotine (and other chemical
13 substances) in their cigarettes, and that cigarettes are manufactured with different
14 chemicals and other substances added to the tobacco. For that reason, cigarettes cannot
15 be considered “fungible.”

16 Finally, to the extent that plaintiff is attempting to allege a theory of “alternative
17 liability” as first articulated in Summers v. Tice, 33 Cal. 2d 80, 82-86 (1948), that theory is
18 inapplicable because “California courts have applied the alternative liability theory only
19 when all potential tortfeasors have been joined as defendants.” Setliff, 32 Cal. App. 4th at
20 1534-35.

21 5. Argument re findings in DOJ case.

22 Finally, the court addresses plaintiff’s argument that the doctrine of nonmutual
23 offensive collateral estoppel/issue preclusion applies in this case to prevent defendants
24 from relitigating issues they have lost in other proceedings. Specifically, plaintiff asks this
25 court to adopt the findings and holdings of the court in United States of America v. Philip
26 Morris USA, Inc., 449 F.Supp. 2d 1 (D.D.C. 2006), affirmed in part and vacated in part, 566
27 F.3d 1095 (D.C. Cir. 2009) (“the DOJ case”).

28 The cited opinion is a 1560-page district court opinion issued in a RICO case

1 brought by the United States Department of Justice against a number of cigarette
2 manufacturers and related entities. The government sought damages and an injunction,
3 but the damages claims were dismissed and the remaining injunctive claims were decided
4 in a bench trial. The case concluded with the court entering a broad injunction against the
5 tobacco companies preventing them from continuing to engage in fraud and deception
6 regarding the health risks of smoking. Plaintiff asserts that because the factual findings
7 and the RICO liability of RJR and Philip Morris were affirmed by the D.C. Circuit,
8 defendants in the present case are collaterally estopped from disputing those findings.²

9 In particular, plaintiff seeks to have the following findings established – (1) that RJR
10 and Philip Morris illegally targeted minors to purchase their cigarette products so as to
11 develop a long-term customer base for those products, and falsely denied they had done
12 so through the time of trial in 2005; (2) that RJR and Philip Morris manipulated the nicotine
13 in their cigarette products through the time of trial in 2005 to increase the addictive impact
14 of the cigarettes on their customers, and falsely denied they had done so through the time
15 of trial; and (3) that RJR and Philip Morris, in concert with other tobacco companies and
16 related entities, engaged in a scheme through the time of trial to misrepresent the health
17 hazards and addictive nature of cigarettes so as to maintain market demand for their
18 products and avoid liability to injured smokers.

19 The court is not persuaded that offensive nonmutual collateral estoppel should be
20 applied with regard to the findings in the DOJ case. “Offensive use of collateral estoppel
21 occurs when the plaintiff seeks to foreclose the defendant from litigating an issue the
22 defendant has previously litigated unsuccessfully in an action with another party.” Pena v.
23 Gardner, 976 F.2d 469, 472 (9th Cir. 1992) (citing Parklane Hosiery Co. v. Shore, 439 U.S.
24 322 (1979)). In other words, a litigant who was not a party to the prior case (here, the
25

26 ² The requested issue preclusion is “nonmutual” because plaintiff was not a party to the
27 prior DOJ case. By contrast, “mutual” issue preclusion involves the exact same parties from
28 the prior litigation. Also, the requested form of issue preclusion is “offensive” because plaintiff
seeks to use the initial case as a sword rather than a shield.

1 plaintiff) can assert collateral estoppel against a litigant who was a party to the prior case
2 (here, defendants) and who lost on the decided issue in the first case.

3 In Parklane Hosiery, the Supreme Court sanctioned the use of offensive nonmutual
4 issue preclusion, but also granted to trial courts “broad discretion to determine when it
5 should be applied.” Id., 439 U.S. at 331. The application of offensive nonmutual issue
6 preclusion is appropriate only if there was a full and fair opportunity to litigate the identical
7 issue in the prior action, the issue was actually litigated in the prior action, the issue was
8 decided in a final judgment, and the party against whom issue preclusion is asserted was a
9 party or in privity with a party to the prior action. Syversdon v. Int’l Business Machines
10 Corp., 472 F.3d 1072, 1078 (9th Cir. 2007). However, as the Court explained in Parklane,
11 these traditional elements are necessary but not sufficient, because the use of non-mutual
12 offensive issue preclusion raises additional policy concerns. See id. at 1078-79; see
13 also Parklane, 439 U.S. at 331-37.

14 It appears that every court that has been asked to apply offensive nonmutual issue
15 preclusion to the findings in the DOJ case has refused to do so. This includes state courts
16 in Massachusetts, Missouri, Maine, and Minnesota, and federal district courts in California,
17 New York, and Arizona. See Shaffer v. R.J. Reynolds Tobacco Co., 860 F.Supp. 2d 991,
18 995-99 (D. Ariz. 2012) (discussing cases). This court agrees with the reasoning of the
19 court in Shaffer and the decisions cited therein, and finds that reasoning generally
20 applicable here.

21 As an initial matter, the court is not persuaded that it would be fair to give preclusive
22 effect to the findings of the court in the DOJ case, given the numerous other inconsistent
23 judgments, with some favoring tobacco defendants and some favoring plaintiffs – or to
24 apply a preclusive effect based on a single adverse judgment. Moreover, plaintiff has not
25 shown that the findings at issue were necessary to the judgment in the DOJ case. Most
26 significantly, the DOJ case was a RICO case tried to the court, and provided only equitable
27 relief; and was not a product liability case tried to a jury, seeking damages (including
28 punitive damages). Thus, giving preclusive effect to findings issued by the DOJ court

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

would arguably violate the Seventh Amendment jury trial rights of defendants in this case.

CONCLUSION

In accordance with the foregoing, the motion to preclude the design-defect testimony of plaintiff's experts Dr. Cummings and Dr. Farone is GRANTED. The motion for summary judgment is GRANTED as to the second cause of action for defective design (and to the first cause of action to the extent it alleges negligent design or negligent failure to warn of defective design); to the third, fourth, sixth, and seventh causes of action for fraud; and to the eighth cause of action for concert of action. The motion is DENIED as to the remaining claims (the fifth cause of action for concealment of health risks of smoking, the first cause of action for negligence to the extent it alleges failure to warn of health risks of smoking, and the tenth cause of action for off-label failure to warn of health risks of smoking).

IT IS SO ORDERED.

Dated: October 22, 2012



PHYLLIS J. HAMILTON
United States District Judge